Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

被引:99
作者
Giancarlo, GM [1 ]
Venkatakrishnan, K [1 ]
Granda, BW [1 ]
von Moltke, LL [1 ]
Greenblatt, DJ [1 ]
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
关键词
CYP2C9; CYP2C19; phenytoin;
D O I
10.1007/s002280100268
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To determine the relative contribution of cytochromes P-450 (CYP) 2C9 and 2C19 to the formation of 5-(-4-hydroxyphenyl)-5-phenylhydantion (HPPH) from phenytoin (PPH). Design: Hydroxylation of PPH to form HPPH was studied in vitro using human liver microsomes and microsomes from cDNA-transfected human lymphoblastoid cells. Results: Formation of HPPH from PPH in liver microsomes had a mean (+/-SEM) apparent Km [substrate concentration corresponding to 50% of maximal reaction velocity (V-max)] of 23.6 +/- 1.8 mu mol/l. Coincubation with the CYP2C9 inhibitor, sulfaphenazole (SPA), at 5 mu mol/l reduced reaction velocity to less than 15% of control values. The mean inhibitor concentration at which 50% inhibition is achieved (IC50 value) for SPA versus PPH hydroxylation (0.49 muM) was similar to the SPA IC50 versus flurbiprofen hydroxylation (0.46 muM) and tolbutamide hydroxylation (0.7-1.5 muM) In contrast, the CYP2C19 inhibitor omeprazole (OME) at 10 mu mol/l produced only a small degree of inhibition. Incubation of PPH with microsomes from cDNA-transfected human lymphoblastoid cells containing CYP1A2, 2A6, 2B6, 2C8, 2D6, 2E1, or 3A4 yielded no detectable formation of HPPH. Only CYP2C9 and 2C19 had PPH hydroxylation activity, with apparent K-m values for the high-affinity component of 14.6 mu mol/l and 24.1 mu mol/l, respectively. Based on V-max values in liver microsomes, the V-max and K-m values in expressed CYPs and the relative abundance of the two isoforms in human liver, CYP2C9, and 2C19 were estimated to have relative contributions of 99% and 10%, respectively, to net intrinsic clearance. Conclusions: Formation of HPPH from PPH is mediated exclusively by CYP2C9 and 2C19, with CYP2C9 playing the major role.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 34 条
[1]  
Äbelö A, 2000, DRUG METAB DISPOS, V28, P966
[2]   A STUDY OF THE INTERACTION BETWEEN OMEPRAZOLE AND PHENYTOIN IN EPILEPTIC PATIENTS [J].
ANDERSSON, T ;
LAGERSTROM, PO ;
UNGE, P .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :329-333
[3]   ABSENCE OF AN INHIBITORY EFFECT OF OMEPRAZOLE AND NIZATIDINE ON PHENYTOIN DISPOSITION, A MARKER OF CYP2C ACTIVITY [J].
BACHMANN, KA ;
SULLIVAN, TJ ;
JAUREGUI, L ;
REESE, JH ;
MILLER, K ;
LEVINE, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (04) :380-382
[4]  
Bajpai M, 1996, DRUG METAB DISPOS, V24, P1401
[5]  
CREPSI CL, 1995, ADV DRUG RES, V26, P179
[6]  
CREPSI CL, 1997, ADV PHARMACOL, V43, P171
[7]  
Cuttle L, 2000, DRUG METAB DISPOS, V28, P945
[8]   RELATIONSHIP BETWEEN PHENYTOIN AND TOLBUTAMIDE HYDROXYLATIONS IN HUMAN LIVER-MICROSOMES [J].
DOECKE, CJ ;
VERONESE, ME ;
POND, SM ;
MINERS, JO ;
BIRKETT, DJ ;
SANSOM, LN ;
MCMANUS, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (02) :125-130
[9]   Ticlopidine inhibits phenytoin clearance [J].
Donahue, S ;
Flockhart, DA ;
Abernethy, DR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (06) :563-568
[10]   Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 [J].
Donahue, SR ;
Flockhart, DA ;
Abernethy, DR ;
Ko, JW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :572-577